Literature DB >> 24679181

Elevated platelet count is a strong predictor of poor prognosis in stage I non-small cell lung cancer patients.

Yongling Ji1, Liming Sheng, Xianghui Du, Guoqin Qiu, Dan Su.   

Abstract

Stage I non-small cell lung cancer (NSCLC) show a highly variable biological behavior which cannot be accurately predicted by the current available prognostic markers. Platelet plays a significant role in cancer cell growth, progression and metastasis. This study aimed to investigate whether preoperative platelet count correlate with clinical prognosis in localized NSCLC. A retrospective clinical analysis was designed for a total of 234 stage I NSCLC patients in our hospital between October 2006 and December 2009. Pre-operative platelet count was measured. The association of platelet count with clinical pathological factors and patient outcome was evaluated. A significant correlation was detected between platelet count and tumor cell differentiation and T stage. Patients with elevated platelet count had an elevated risk of disease progression and death compared to patients with normal platelet count. The hazard ratio was 5.314 (95% confidence interval [CI] 2.750-10.269) for disease progression and 3.139 (95% CI 1.227-8.034) for death. The trend linking increasing platelet count with risk was also statistically significant for both the outcomes (p < 0.05). These finding demonstrate that preoperative platelet count is a useful predictor of high risk progression and poor prognosis in stage I NSCLC patients.

Entities:  

Keywords:  Lung cancer; platelet, prognosis; stage I disease

Mesh:

Year:  2014        PMID: 24679181     DOI: 10.3109/09537104.2014.888547

Source DB:  PubMed          Journal:  Platelets        ISSN: 0953-7104            Impact factor:   3.862


  26 in total

1.  Prognostic role of elevated platelet count in patients with lung cancer: a systematic review and meta-analysis.

Authors:  Xi Zhang; Yuge Ran
Journal:  Int J Clin Exp Med       Date:  2015-04-15

2.  Prognostic value of combined platelet, fibrinogen, neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in patients with lung adenosquamous cancer.

Authors:  Yu-Qian Wang; Qiong-Jie Zhi; Xin-Yue Wang; Dong-Sheng Yue; Kai Li; Ri-Cheng Jiang
Journal:  Oncol Lett       Date:  2017-07-24       Impact factor: 2.967

Review 3.  Motivation for Launching a Cancer Metastasis Inhibition (CMI) Program.

Authors:  Jill M Pulley; Rebecca N Jerome; Martin L Ogletree; Gordon R Bernard; Robert R Lavieri; Nicole M Zaleski; Charles C Hong; Jana K Shirey-Rice; Carlos L Arteaga; Ingrid A Mayer; Kenneth J Holroyd; Rebecca S Cook
Journal:  Target Oncol       Date:  2018-02       Impact factor: 4.493

4.  Elevated Platelet Count Appears to Be Causally Associated with Increased Risk of Lung Cancer: A Mendelian Randomization Analysis.

Authors:  Ying Zhu; Yongyue Wei; Ruyang Zhang; Xuesi Dong; Sipeng Shen; Yang Zhao; Jianling Bai; Demetrius Albanes; Neil E Caporaso; Maria Teresa Landi; Bin Zhu; Stephen J Chanock; Fangyi Gu; Stephen Lam; Ming-Sound Tsao; Frances A Shepherd; Adonina Tardon; Ana Fernández-Somoano; Guillermo Fernandez-Tardon; Chu Chen; Matthew J Barnett; Jennifer Doherty; Stig E Bojesen; Mattias Johansson; Paul Brennan; James D McKay; Robert Carreras-Torres; Thomas Muley; Angela Risch; Heunz-Erich Wichmann; Heike Bickeboeller; Albert Rosenberger; Gad Rennert; Walid Saliba; Susanne M Arnold; John K Field; Michael P A Davies; Michael W Marcus; Xifeng Wu; Yuanqing Ye; Loic Le Marchand; Lynne R Wilkens; Olle Melander; Jonas Manjer; Hans Brunnström; Rayjean J Hung; Geoffrey Liu; Yonathan Brhane; Linda Kachuri; Angeline S Andrew; Eric J Duell; Lambertus A Kiemeney; Erik Hfm van der Heijden; Aage Haugen; Shanbeh Zienolddiny; Vidar Skaug; Kjell Grankvist; Mikael Johansson; Penella J Woll; Angela Cox; Fiona Taylor; Dawn M Teare; Philip Lazarus; Matthew B Schabath; Melinda C Aldrich; Richard S Houlston; John McLaughlin; Victoria L Stevens; Hongbing Shen; Zhibin Hu; Juncheng Dai; Christopher I Amos; Younghun Han; Dakai Zhu; Gary E Goodman; Feng Chen; David C Christiani
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-01-30       Impact factor: 4.254

5.  Quantitative proteomics of hamster lung tissues infected with SARS-CoV-2 reveal host factors having implication in the disease pathogenesis and severity.

Authors:  Voddu Suresh; Varshasnata Mohanty; Kiran Avula; Arup Ghosh; Bharati Singh; Rajendra Kumar Reddy; Deepti Parida; Amol Ratnakar Suryawanshi; Sunil Kumar Raghav; Soma Chattopadhyay; Punit Prasad; Rajeeb Kumar Swain; Rupesh Dash; Ajay Parida; Gulam Hussain Syed; Shantibhusan Senapati
Journal:  FASEB J       Date:  2021-07       Impact factor: 5.834

6.  Kinetics of postdiagnosis platelet count with overall survival of pancreatic cancer: a counting process approach.

Authors:  Yuanyuan Xiao; Hua Xie; Zhihui Xie; Zhenyi Shao; Wen Chen; Guoyou Qin; Naiqing Zhao
Journal:  Cancer Med       Date:  2016-02-10       Impact factor: 4.452

7.  Combination of platelet count and lymphocyte to monocyte ratio is a prognostic factor in patients undergoing surgery for non-small cell lung cancer.

Authors:  Wei Liu; Minwen Ha; Nanchang Yin
Journal:  Oncotarget       Date:  2017-06-01

Review 8.  Cancer and Thrombosis: The Platelet Perspective.

Authors:  Claire K S Meikle; Clare A Kelly; Priyanka Garg; Leah M Wuescher; Ramadan A Ali; Randall G Worth
Journal:  Front Cell Dev Biol       Date:  2017-01-05

Review 9.  Inflammatory cell-associated tumors. Not only macrophages (TAMs), fibroblasts (TAFs) and neutrophils (TANs) can infiltrate the tumor microenvironment. The unique role of tumor associated platelets (TAPs).

Authors:  Violetta Dymicka-Piekarska; Olga M Koper-Lenkiewicz; Justyna Zińczuk; Ewa Kratz; Joanna Kamińska
Journal:  Cancer Immunol Immunother       Date:  2020-11-03       Impact factor: 6.968

10.  Cervical cancer systemic inflammation score: a novel predictor of prognosis.

Authors:  Ru-Ru Zheng; Min Huang; Chu Jin; Han-Chu Wang; Jiang-Tao Yu; Lin-Chai Zeng; Fei-Yun Zheng; Feng Lin
Journal:  Oncotarget       Date:  2016-03-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.